E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) |
|
E.1.1.1 | Medical condition in easily understood language |
This trial aims to investigate metastasised and / or locally advanced neuroendocrine tumours (NET) in patients with pancreatic NET or non-functional gastroenteric NET. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10077559 |
E.1.2 | Term | Gastroenteropancreatic neuroendocrine tumour disease |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to demonstrate the efficacy of PRRT with 177Lu-edotreotide to prolong median progression-free survival (mPFS) in patients with inoperable, progressive, SSTR+ GEP-NET, compared to everolimus |
|
E.2.2 | Secondary objectives of the trial |
1. To assess overall survival (OS) during study period 2. To determine objective response rates (ORR) 3. To determine disease control rates (DCR) 4. To determine the duration of disease control (DDC) 5. To determine functional response rates (FRR) 6. To assess the safety and tolerability of 177Lu-edotreotide in GEP-NET patients 7. To determine the health-related quality of life (HRQL) in GEP-NET patients during and after therapy 8. To evaluate symptomatic tumour response 9. To evaluate the impact of patient characteristics 10. To evaluate the impact of tumour histology |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Sub-study A: Repetitive Full Dosimetry Imaging (D1 – D4): Objective: The total absorbed doses (AD) to kidneys and tumour from four cycles of 177Lu-edotreotide (D1 – D4) will be estimated, by linear extrapolation of the AD measured during D1 with 7.5 GBq to the full dose of 30 GBq. Dosimetry will be measured, using serial planar and single time point SPECT imaging. To verify the accuracy of total AD estimations, based on a linear extrapolation of AD measured during D1, full dosimetric imaging will be repeated during subsequent cycles (D2 – D4) in a subgroup of approximately 20 patients, ready and able to undergo repetitive dosimetric imaging.
Sub-study B: 3D Dosimetry SPECT/CT Imaging: Objective: Abdominal SPECT images (1-2 bed positions, covering liver, kidneys, tumour, as appropriate) will be acquired in a subgroup of approximately 20 patient of 177Lu-edotreotide group in addition to the compulsatory planar images at the following time points of 0.5, 6, 24, and 72 – 96 h after injection of 177Lu-edotreotide. SPECT imaging will be performed after planar imaging. The absorbed doses determined by 3D dosimetry, will be analysed in comparison to absorbed doses values obtained by planar (2D) and hybrid (2D/3D) dosimetry. |
|
E.3 | Principal inclusion criteria |
All patients must meet all of the following criteria: 1. Written informed consent 2. Male or female ≥ 18 years of age 3. Histologically and clinically confirmed diagnosis of well-differentiated neuro-endocrine tumour of non-functional gastroenteric origin (GE-NET) or both functional or non-functional pancreatic origin (P-NET), grade G1 or G2 (Ki-67 < 20%), unresectable or metastatic 4. Availability of existing biopsy specimen from primary tumour or metastasis or, if unavailable, willingness to undergo current biopsy for secondary central analysis 5. Measurable disease per RECIST 1.1, on CT/MRI scans, defined as at least 1 lesion with ≥ 1 cm in longest diameter, and ≥ 2 radiological tumour lesions in total. A maximum of 5 target lesions visible on CT/MRI will be defined, thereof not more than 2 lesions per organ 6. Somatostatin receptor positive (SSTR+) disease, as evidenced by SSTR imaging (SRI) within 4 months prior to randomisation, by: • 68Ga-based SSTR PET imaging (e.g. using 68Ga-edotreotide or 68Ga-DOTATATE), or • 111In-pentetreotide SSTR SPECT/planar imaging, or • 99mTc-octreotide SSTR SPECT/planar imaging All target lesions and ≥ 90% of non-target lesions need to be positive for SSTR, demonstrated by adequate tracer uptake, being defined as being “clearly differentiable from background” 7. Radiological disease progression, defined as: • Progressive disease per RECIST 1.1. criteria, eviden-ced by consecutive morphological imaging (CT or MRI) with ≥ 90 days interval during the 12 months prior to randomisation 8. Karnofsky performance status (KPS) scale ≥ 70 9. Life expectancy of at least 6 months 10. Glomerular filtration rate (GFR, MDRD) ≥ 60 mL/min/1.73 m^2 |
|
E.4 | Principal exclusion criteria |
A patient will be excluded from participation in the trial if one or more of the following criteria are met: 1. Known hypersensitivity to edotreotide or everolimus 2. Known hypersensitivity to DOTA, lutetium-177, or any excipient of edotreotide or everolimus 3. Known hypersensitivity to lysin, arginin, or any excipient of the nephroprotective amino acid solution 4. Prior exposure to any peptide receptor radiotherapy (PRRT), including 177Lu-edotreotide, 90Y-edotreotide or other SSTR-targeting agents (e.g. 177Lu-octreotate or high-dose 111In-pentetreotide) 5. Prior therapy with mTor inhibitors 6. Prior EFR (extended field radiation) to GEP-NET lesions or radioembolisation therapy (e.g. 90Y microspheres, 131I-lipiodol) with administration to the liver 7. Therapy with an investigational compound and/or medical device within 30 days or 5 half-life periods (whichever is longer) prior to randomisation 8. Current therapy with any prohibited medication 9. Ongoing toxicity grade 2 from previous standard or investigational therapies (Common Terminology Criteria for Adverse Events [CTCAE] version 4.03) 10. Indication for surgical lesion removal with curative potential 11. Planned (for the period of study participation): chemotherapy, immunotherapy, radiation therapy, chemo-embolisation, bland embolisation, radio-embolisation, treatment with cyclosporine-A 12. Neuroendocrine tumours, not meeting the inclusion criteria: • With known non-GEP-NET origin (e.g. pulmonary or gonadal primaries) • Functional GE-NET • NET with unknown primaries (CUP), manifesting as liver metastases • Poorly differentiated neuroendocrine carcinomas (grade G3) • NET for which no histological specimen for secondary histological analysis can be obtained 13. Total hepatic tumour burden > 70% 14. Brain metastases 15. Secondary malignoma within previous 5 years (except basalioma) 16. Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic), that may interfere with the objectives of the study or with the safety or compliance of the subject, as judged by the investigator 17. Renal, hepatic, cardiovascular, or haematological organ dysfunction, potentially interfering with the safety of the study treatments, as follows: • Renal o Serum creatinine ≥ 1.5 x ULN, or creatinine clearance (GFR, MDRD) < 60 mL/min/1.73 m^2 o Serum potassium > 5.0 mmol/l o Renal obstruction o Known nephropathy from any cause • Hepatic o Total bilirubin > 2.5 x ULN o AST or ALT > 2.5 x ULN o Alkaline phosphatase > 5 x ULN o Albumin < 3 g/dL, unless prothrombin time is within normal range o Known cirrhosis or other distinctly restricted liver function • Cardiovascular o New York Heart Association classification III & IV o Uncontrolled hypertension • Haematopoietic o Platelets ≤ 80 * 10^9/mL o Absolute neutrophil count (ANC) < 1,000/mL 18. Pregnant or breast-feeding. Female patients of childbearing potential or male patients with female partners of childbearing potential not willing to practice effective contraception during the study period in the everolimus group and, in the PRRT group, for 66 days (10 half lives of 177Lu) after the last treatment cycle. 19. Subjects not able to declare meaningful informed consent on their own (e.g. with legal guardian for mental disorders) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint is progression-free survival (PFS). Diagnosis of progression will be established based on morphological imaging (MRI and/or CT) according to RECIST 1.1. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Progression-free survival (PFS) will be determined as time elapsed between randomisation and the date of first objective report of tumour progression (evaluated by RECIST criteria, 1.1) |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints include overall survival (OS), parameters of morphological and functional tumour response, safety, health-related quality of life (HRQL). Furthermore, patient and tumour characteristics, as well as the degree of 177Lu-edotreotide uptake will be exploratively analysed as possible predictors of PRRT efficacy. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Dosimetry: To assess differences in tumour and kidney radiation dose estimates, obtained with 2D compared to hybrid (2D/3D) and 3D (SPECT) imaging |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 19 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Austria |
France |
Germany |
Italy |
Netherlands |
Poland |
South Africa |
Switzerland |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the last visit of the last patient or the last date of follow-up of toxicities, if required (whichever is the later). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |